Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis.

Trial Profile

Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer; Carcinomatous meningitis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HIT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Feb 2016 Planned End Date changed from 1 Jun 2017 to 1 May 2019 as per ClinicalTrials.gov record.
    • 05 Feb 2016 Planned primary completion date changed from 1 May 2015 to 1 Sep 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top